AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 202 min read$CAPR

CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact SueWallSt

Capricor Therapeutics (CAPR) faces a securities class action lawsuit after shares dropped 78.7% following FDA briefing documents and an advisory committee vote against its drug. Investors allege undisclosed changes to the statistical analysis plan. The class period is December 17, 2025, to July 26, 2026, with a lead plaintiff deadline of September 28, 2026.

Original reporting
prnewswire.com
Published Aug 20, 2026, 5:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 7:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
CAPR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Capricor Therapeutics Securities Lawsuit - Contact SueWallSt — source image
Source · prnewswire.com
Decision brief

The 30-second read

$CAPRBearishLow
01

Why it matters

The filing introduces legal risk and may affect investor confidence, possibly leading to further price weakness.

02

Market read

The lawsuit adds a new catalyst for CAPR, reinforcing the recent downtrend and highlighting litigation risk in the biotech sector.

03

What to watch

Potential FDA resubmission timeline and upcoming data readouts are not addressed in the lawsuit.

Relevance 7/10Novelty 7/10Timing: lead plaintiff deadline Sep 28 2026

Background

Capricor Therapeutics (NASDAQ: CAPR) saw a 78.7% drop after FDA briefing documents revealed unagreed statistical analysis plan changes, prompting a class action filing.

Company-level read

Ticker impact

$CAPRBearishMedium confidence
Context

A securities class action was filed alleging undisclosed FDA briefing changes that caused a 78.7% share decline.

Expected impact

Further downside risk of 5‑10% if settlement talks stall; upside limited to settlement premium.

Evidence & confidence

Legal exposure adds uncertainty; no new financing or operational news, but litigation can trigger short‑seller activity.

Market effects

Sector

Biotech litigation risk highlighted; may cause broader caution in small‑cap biotech stocks.

Regional

U.S. biotech sector may see modest sell pressure.

Global

Limited to investors tracking U.S. biotech litigation.

Counterpoint

What could challenge this read

If the company can secure a quick settlement, the stock could rebound on reduced uncertainty.

Key entities

  • Company
    Capricor Therapeutics

    Biotech firm developing deramiocel for DMD‑associated cardiomyopathy.

  • Law Firm
    Levi & Korsinsky LLP

    Securities litigation firm representing the class.

Read at source← All news

Related articles

AUG 24
$CAPRMedAI 8/10

Why is Capricor Therapeutics stock rallying today?

Capricor Therapeutics (CAPR) stock rose 2.6% after the FDA extended its review period for Deramiocel to November 22, 2026, due to new data submission. Shares initially surged to $8.015 but retreated amid broader market declines and regulatory concerns. Analysts have mixed views, with Cantor Fitzgerald targeting $28. The stock's 52-week range is $2.96 to $40.37.

investing.com2 min
AUG 24
$CAPRMed

Capricor Therapeutics stock surges on FDA review extension

Capricor Therapeutics (CAPR) shares rose 29% after the FDA extended the review period for its Deramiocel BLA to November 22, 2026. The extension follows the submission of additional Phase 3 HOPE-3 data supporting a refined indication for Duchenne muscular dystrophy. The FDA accepted the amendment, citing significant unmet medical need.

investing.com2 min
AUG 24
$CAPRLow

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR

Capricor Therapeutics (CAPR) faces a class action lawsuit for alleged securities violations. The DJS Law Group claims the company made false statements regarding its clinical data analysis and FDA agreement for Deramiocel. Shareholders who bought shares between December 17, 2025, and July 26, 2026, are encouraged to contact the firm by September 28, 2026, to discuss potential recovery.

prnewswire.com1 min
AUG 21
$CAPRMed

/C O R R E C T I O N -- Kessler Topaz Meltzer & Check, LLP/

Capricor Therapeutics (CAPR) faces a securities fraud class action lawsuit for alleged misstatements about its lead product candidate's statistical analysis plan and FDA compliance. The lawsuit covers investments between December 17, 2025, and July 26, 2026, with a deadline to seek lead plaintiff status on September 28, 2026. The FDA's briefing documents revealed unapproved changes to the analysis plan, causing CAPR's stock to drop 64% on July 27, 2026.

prnewswire.com2 min
AUG 21
$CAPRLow

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

A class action lawsuit was filed against Capricor Therapeutics (NASDAQ: CAPR) by investors who purchased shares between December 17, 2025, and July 26, 2026. The lawsuit alleges securities fraud, claiming the company misrepresented its lead product candidate's statistical analysis plan and FDA compliance. The FDA's briefing documents revealed disagreements with Capricor's changes, causing the stock to drop 64%. Investors have until September 28, 2026, to seek lead plaintiff status.

prnewswire.com2 min